DEF: Bone Biologics Seeks Stockholder Approval for Reverse Stock Split and Amended Equity Incentive Plan

Bone Biologics is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.

Summary

• Bone Biologics Corporation is holding its Annual Meeting of Stockholders on May 30, 2025.
• The meeting will address several key proposals, including the election of four directors, an advisory vote on executive compensation, and a reverse stock split.
• The company is seeking approval for a reverse stock split in a range of 1-for-2.5 to 1-for-10, at the discretion of the board of directors.
• Stockholders will also vote on an amendment to the 2015 Equity Incentive Plan, subject to the reverse stock split being approved, to increase the number of shares available for issuance.
• The company is also asking stockholders to ratify the appointment of Weinberg & Company, P.A., as its independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Additionally, stockholders will vote on a proposal to approve an adjournment of the Annual Meeting, if necessary.
• The Board of Directors has fixed April 17, 2025, as the record date for determining stockholders entitled to vote at the Annual Meeting.
• As of the record date, there were 3,271,042 shares of common stock outstanding.
• The Board recommends voting FOR all proposals.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focused on presenting proposals for stockholder vote. The need for a reverse stock split suggests some financial challenges, but the potential benefits of the split and the equity incentive plan amendment are presented positively.

Positives

• The reverse stock split is intended to help the company maintain its listing on the Nasdaq Capital Market.
• The increased number of shares under the equity incentive plan will allow the company to attract and retain key personnel.
• The Board believes that the reverse stock split could improve the marketability and liquidity of the Common Stock and encourage interest and trading in the Common Stock.

Negatives

• The company received a deficiency letter from Nasdaq for not complying with the minimum bid price rule.
• Reverse stock splits can have a negative perception among investors.
• The stock prices of some companies that have effected reverse stock splits have subsequently declined.
• The proposed Reverse Stock Split may decrease the liquidity of our Common Stock and result in higher transaction costs.

Risks

• Failure to approve the reverse stock split may have serious, adverse effects on the Company and its stockholders.
• The company may be unable to regain compliance with the Minimum Bid Price Rule and maintain compliance with Nasdaqs other continued listing standards.
• The market price of the Common Stock may decrease due to factors unrelated to the Reverse Stock Split, including our future performance, similar to the prior reverse stock split by the Company.

Future Outlook

The company aims to maintain its Nasdaq listing and improve the marketability and liquidity of its common stock through the proposed reverse stock split.

Industry Context

Reverse stock splits are often used by companies facing delisting from major exchanges to regain compliance with minimum share price requirements. The amendment to the equity incentive plan is a common practice to ensure the company can continue to attract and retain talent.

Comparison to Industry Standards

• Many companies facing similar circumstances, such as delisting warnings from Nasdaq, have implemented reverse stock splits.
• Comparable companies in the biotechnology sector, such as Verastem and Purple Biotech Ltd, have directors serving on the Bone Biologics board.
• The executive compensation structure, including base salary, bonus potential, and equity awards, is generally in line with industry standards for small-cap biotechnology companies.

Stakeholder Impact

• Shareholders will be impacted by the potential reverse stock split, which will reduce the number of shares they hold.
• Employees and consultants may be impacted by the amendment to the equity incentive plan, which could increase the number of shares available for stock awards.
• The company's ability to maintain its Nasdaq listing will impact all stakeholders.

Next Steps

• Stockholder vote on the proposals at the Annual Meeting on May 30, 2025.
• Board decision on whether to implement the reverse stock split and at what ratio, if the proposal is approved.
• Filing of the Reverse Split Certificate with the Delaware Secretary of State, if the Board decides to proceed with the reverse stock split.

Key Dates

Keywords

reverse stock split, proxy statement, annual meeting, equity incentive plan, directors, executive compensation, Weinberg & Company, Bone Biologics, stockholders